Klacid (Clarithromycin)

Clarithromycin works by binding to the bacterial 50S ribosomal subunit, blocking the translocation step of protein synthesis. This inhibition stops peptide chain elongation, leading to a bacteriostatic effect against susceptible organisms and reducing toxin production in certain pathogens, thereby helping to clear the infection.

The exact dosing regimen for Klacid is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals adjust the dose to achieve optimal therapeutic outcomes while minimizing risk.

Clarithromycin is classified as pregnancy category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Clarithromycin is excreted in breast milk; breastfeeding decisions should be made in consultation with a healthcare provider.

To order Klacid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Klacid (clarithromycin) belongs to the macrolide class, similar to azithromycin and erythromycin. Compared with azithromycin, clarithromycin generally has a broader spectrum against certain Gram‑positive organisms and a higher potential for drug‑drug interactions due to CYP3A4 inhibition. Choice between agents depends on local resistance patterns, patient tolerance, and specific infection characteristics.

Klacid should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Once reconstituted, follow the manufacturer’s guidance on stability and use within the recommended time frame to maintain potency.

Klacid is supplied as an intravenous solution and is administered by slow intravenous infusion under the supervision of qualified healthcare personnel. The infusion rate and duration are determined by the prescribing clinician based on the patient’s condition and the specific therapeutic protocol.

The most serious risks include hepatotoxicity, which may present as elevated liver enzymes or liver injury; QT‑interval prolongation that can lead to potentially life‑threatening arrhythmias; and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of liver dysfunction, cardiac rhythm changes, and allergic responses during therapy.

Klacid should be avoided in patients with known hypersensitivity to clarithromycin or other macrolide antibiotics. It is also contraindicated in individuals with a history of significant QT prolongation, those taking other strong QT‑prolonging drugs, and patients with severe hepatic impairment where the risk outweighs benefit. Clinical judgment is required for all other cases.